+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Human NGAL Test Kit Market - Global Forecast 2025-2030- Product Image
Human NGAL Test Kit Market - Global Forecast 2025-2030- Product Image
Sale

Human NGAL Test Kit Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 181 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6130225
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
Neutrophil Gelatinase-Associated Lipocalin has rapidly emerged as a pivotal biomarker for the early detection of acute kidney injury, signaling a paradigm shift in clinical diagnostics. Historically, reliance on serum creatinine resulted in delayed identification of renal impairment. Now, quantification of NGAL concentrations in biological fluids offers clinicians unprecedented lead time to intervene, thereby reducing patient morbidity.

Moreover, the evolution of assay technologies has broadened NGAL’s role beyond nephrology. Researchers are exploring its utility in monitoring chronic kidney disease progression and probing its expression in oncological and inflammatory contexts. These expanded applications underscore the versatility of NGAL testing and highlight its potential to inform precision medicine protocols across diverse therapeutic areas.

This executive summary synthesizes critical developments in assay innovation, regulatory environment shifts, and adoption dynamics. It offers a distilled view of segmentation complexities, regional drivers, and competitive moves. Through a thorough yet accessible presentation, this introduction sets the stage for actionable insights that stakeholders can leverage to refine strategy and reinforce diagnostic excellence.

Unveiling the Transformative Shifts Altering the Dynamics of NGAL Test Deployment Across Healthcare Settings and Research Applications

Breakthroughs in assay technology have redefined the deployment of NGAL test kits across both central laboratories and point-of-care settings. Transitioning from manual enzyme-linked immunosorbent approaches to fully automated chemiluminescent immunoassays has accelerated turnaround times and enhanced sensitivity. Simultaneously, lateral flow devices with integrated reader platforms are empowering bedside diagnostics, facilitating rapid decision making within critical care units.

Furthermore, the integration of advanced analytics and connectivity solutions into immunoturbidimetric systems has streamlined data management and supported compliance with evolving regulatory requirements. These enhancements align with value-based care imperatives, as healthcare providers seek measurable improvements in patient outcomes and cost efficiencies. Reimbursement frameworks are increasingly recognizing biomarker-driven diagnostics, further stimulating adoption.

In parallel, research applications have diversified, with laboratories harnessing NGAL assays to investigate sepsis markers and inflammatory pathways. This cross-disciplinary expansion is catalyzing the development of multiplex platforms and bespoke assay kits, positioning NGAL testing as a versatile component of future diagnostic toolkits.

Assessing the Cumulative Impact of United States Tariff Revisions on the Importation and Accessibility of NGAL Test Kits in 2025

Recent revisions to United States tariff policies have introduced complexity into the supply chain logistics of diagnostic reagents, including NGAL test kits. Adjustments to import duties under targeted trade measures have resulted in elevated costs for raw materials and finished products, compelling manufacturers and distributors to reassess pricing structures. Consequently, procurement teams are navigating a delicate balance between maintaining affordability and preserving quality standards.

Moreover, these tariff developments have prompted strategic recalibrations in sourcing. Some suppliers are exploring alternative manufacturing hubs with favorable trade agreements to mitigate duty burdens. Collaborative partnerships with regional distributors have emerged as a cost-containment measure, enabling more agile inventory management and localized customization of testing solutions.

As stakeholders adapt to this evolving landscape, transparency in cost modeling and proactive negotiations with logistics providers are proving critical. Aligning procurement strategies with regulatory forecasts and potential policy shifts will be essential to sustain reliable access to NGAL testing resources throughout 2025 and beyond.

Extracting Key Segmentation Insights Spanning Product Types End Users Distribution Channels Applications and Sample Types to Illuminate Market Nuances

In examining product type segmentation, chemiluminescence immunoassays dominate in high-throughput laboratories, with direct CLIA formats offering streamlined workflows and indirect CLIA variants providing enhanced signal amplification for low-abundance analytes. Enzyme-linked immunosorbent assays retain relevance through automated ELISA systems that boost consistency, while manual ELISA kits continue to serve research labs seeking flexibility. Immunoturbidimetric assays and lateral flow solutions complement these formats, catering to diverse throughput demands.

Turning to end users, academic and research laboratories leverage manual protocols and custom panel configurations to investigate NGAL’s role in novel therapeutic pathways. Diagnostic laboratories prioritize automated platforms to meet stringent turnaround requirements. Hospital based and reference laboratory segments benefit from integrated analytics, while point of care testing facilities increasingly adopt portable lateral flow tools to guide urgent treatment decisions.

Distribution channel insights reveal direct tender agreements as a cornerstone for large hospital networks, whereas global and regional distributors enhance market coverage by managing multi-vendor portfolios. Online sales channels are facilitating rapid procurement for research institutions, blending ease of access with technical support. Application-oriented segmentation underscores acute kidney injury detection as the primary diagnostic use, with chronic kidney disease monitoring expanding adoption. Neonatal and population screening initiatives are fueling demand for high sensitivity assays. Sample type considerations reflect the prevalence of plasma testing with citrated or EDTA preparations, while serum, urine, and whole blood assays address specific clinical and ambulatory scenarios.

Unraveling the Regional Dynamics Driving NGAL Test Kit Adoption Patterns across Americas EMEA and Asia Pacific Territories

In the Americas region, robust healthcare infrastructure and well-established reimbursement protocols have driven widespread adoption of high-performance NGAL assays. Key hospital networks in North America have integrated point of care platforms to expedite acute kidney injury interventions, while academic centers in Latin America are advancing research collaborations that explore NGAL’s biomarker potential in broader disease areas.

Europe, Middle East & Africa landscapes present a mosaic of regulatory frameworks and funding mechanisms. Western European laboratories demonstrate mature CLIA and ELISA integration, supported by centralized reference facilities that emphasize standardization. Conversely, emerging economies in the Middle East and Africa are gradually embracing portable immunoassay solutions to extend diagnostic reach into underserved communities, catalyzed by health-system modernization initiatives.

Asia-Pacific markets offer a dynamic growth environment shaped by rapid urbanization and expanding clinical research activities. Leading healthcare hubs in East Asia have championed innovative lateral flow and immunoturbidimetric platforms, whereas South and Southeast Asian institutions are prioritizing cost-efficient assay kits that balance performance with resource constraints. Collaborative trials and public-private partnerships are elevating NGAL’s visibility as a critical diagnostic adjunct across the region.

Highlighting the Strategic Maneuvers and Collaborations of Prominent Stakeholders Shaping the NGAL Test Kit Market Spectrum

Global industry leaders are reinforcing their portfolios through strategic R&D investments and cross-sector partnerships. Key players with established immunodiagnostic platforms have expedited NGAL assay validation by leveraging modular analyzer architectures, ensuring seamless integration for end users. Simultaneously, companies specializing in rapid lateral flow diagnostics have broadened their footprint through alliances with hospital consortia and academic research networks.

Competitive differentiation has emerged through the pursuit of regulatory clearances in multiple jurisdictions. Organizations that achieve streamlined approval pathways unlock access to critical procurement channels, from hospital tenders to point of care implementations. Furthermore, collaborative efforts among kit developers and reagent suppliers are fostering co-branded offerings that optimize reagent stability and throughput performance.

Emerging contenders are challenging incumbents by championing niche applications such as neonatal and population screening. By coupling assay enhancements with digital reporting tools, these innovators are reshaping service delivery models and compelling established stakeholders to reassess product roadmaps. The resultant landscape is one of heightened innovation velocity and intensified focus on customer-centric solutions.

Crafting Actionable Strategies to Propel Leadership and Innovation in NGAL Test Kit Development and Market Penetration Tactics

Industry leaders should prioritize the development of integrated assay suites that couple NGAL quantification with complementary biomarkers to deliver comprehensive renal health profiles. By investing in multiplex platform compatibility, manufacturers can address diverse clinical workflows and reinforce value propositions for both centralized labs and point of care settings. Moreover, establishing standardized calibration protocols will enhance cross-platform comparability and bolster clinician confidence.

Engagement with regulatory bodies early in the product lifecycle can accelerate approval timelines and support the framing of reimbursement criteria that reflect NGAL’s clinical utility. Building strategic alliances with hospital networks and reference laboratories will facilitate pilot implementations that generate real-world evidence, underpinning favorable coverage decisions.

To capture growth in emerging geographies, companies should deploy flexible distribution models that combine direct tender negotiations with regional partner ecosystems. Tailored training programs and digital support portals will ensure adoption success, particularly in resource-constrained environments. Finally, continuous investment in assay automation and data analytics infrastructure will sustain competitive differentiation and support scalable market expansion.

Detailing the Research Methodology Framework Employing Rigorous Data Collection Analytical Techniques and Quality Assurance Protocols

This research initiative was grounded in a rigorous dual-phase approach, commencing with an extensive review of peer-reviewed literature, regulatory filings, and patent databases to establish a comprehensive knowledge base of NGAL assay evolution. Secondary data sources included clinical trial registries and white papers, which informed the identification of emerging trends and unmet diagnostic needs. These findings were triangulated with product catalogs and technical specifications from leading assay manufacturers.

Primary insights were garnered through structured interviews with key opinion leaders spanning nephrology, clinical chemistry, and laboratory management. These discussions yielded nuanced perspectives on workflow integration challenges, performance benchmarks, and end user preferences. Supplementary consultations with distribution channel experts illuminated the operational considerations underpinning reagent logistics and service support frameworks.

All data underwent systematic validation through cross-referencing among multiple sources, followed by iterative internal reviews to ensure consistency and accuracy. Quality assurance protocols encompassed checks for methodological rigor, data integrity, and relevance to strategic decision making. The resulting analysis offers stakeholders a robust evidence base for informed planning and resource allocation.

Synthesizing Key Findings and Forward-Looking Perspectives to Consolidate the Strategic Narrative of NGAL Test Kit Innovation

The analysis presented herein underscores the critical role that NGAL testing plays in enabling earlier intervention for renal dysfunction and its expanding relevance across clinical research domains. Advancements in assay automation and lateral flow portability have broadened access to rapid diagnostics, while strategic partnerships and regulatory engagements have shaped a dynamic competitive environment. Segmentation insights reveal the nuanced requirements of diverse end users, from high-volume central labs to decentralized point of care settings.

Looking ahead, stakeholders who align product development with evolving reimbursement models and invest in data-driven value demonstrations will be best positioned to capture new growth avenues. Regional adoption patterns highlight the importance of adaptable distribution strategies and localized technical support. By synthesizing these findings into cohesive strategic roadmaps, industry players can drive sustainable innovation and reinforce the impact of NGAL testing on patient care pathways.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Type
    • Chemiluminescence Immunoassay
      • Direct Clia
      • Indirect Clia
    • Enzyme-Linked Immunosorbent Assay
      • Automated Elisa
      • Manual Elisa
    • Immunoturbidimetric Assay
    • Lateral Flow Assay
  • End User
    • Academic And Research Laboratories
    • Diagnostic Laboratories
    • Hospitals
      • Hospital Based Laboratories
      • Reference Laboratories
    • Point Of Care Testing Facilities
  • Distribution Channel
    • Direct Tender
    • Distribution Partners
      • Global Distributors
      • Regional Distributors
    • Online Sales
  • Application
    • Diagnostic
      • Acute Kidney Injury Detection
      • Chronic Kidney Disease Monitoring
    • Research
    • Screening
      • Neonatal Screening
      • Population Screening
  • Sample Type
    • Plasma
      • Citrated Plasma
      • Edta Plasma
    • Serum
    • Urine
    • Whole Blood
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Abbott Laboratories
  • BioPorto Diagnostics A/S
  • bioMérieux SA
  • Randox Laboratories Ltd.
  • BÜHLMANN Laboratories AG
  • Gentian AS
  • Diazyme Laboratories, Inc.
  • Sekisui Medical Co., Ltd.
  • BioVendor - Laboratorní medicína, a.s.
  • R&D Systems, Inc.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rising adoption of point-of-care NGAL testing devices in emergency departments for acute kidney injury diagnosis
5.2. Integration of NGAL biomarkers into comprehensive multiplex renal panels by leading diagnostics providers
5.3. Growth of home-based NGAL testing solutions for early detection of kidney dysfunction in chronic disease management
5.4. Advances in nanotechnology-enhanced NGAL assay sensitivity enabling ultra-low biomarker detection thresholds
5.5. Regulatory approvals of automated high-throughput NGAL test systems reducing turnaround time in clinical laboratories
5.6. Collaborations between biotech startups and academic research centers to develop NGAL-based prognostic tools for heart failure patients
5.7. Expansion of NGAL testing applications beyond nephrology into oncology and infectious disease diagnostics
5.8. Implementation of AI-driven analytics for interpreting NGAL test results and predicting patient outcomes more accurately
5.9. Cost reduction in NGAL test kit manufacturing through reagent optimization and lean production processes
5.10. Increasing reimbursement coverage for NGAL diagnostic tests by major healthcare payers improving market access
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Human NGAL Test Kit Market, by Product Type
8.1. Introduction
8.2. Chemiluminescence Immunoassay
8.2.1. Direct Clia
8.2.2. Indirect Clia
8.3. Enzyme-Linked Immunosorbent Assay
8.3.1. Automated Elisa
8.3.2. Manual Elisa
8.4. Immunoturbidimetric Assay
8.5. Lateral Flow Assay
9. Human NGAL Test Kit Market, by End User
9.1. Introduction
9.2. Academic And Research Laboratories
9.3. Diagnostic Laboratories
9.4. Hospitals
9.4.1. Hospital Based Laboratories
9.4.2. Reference Laboratories
9.5. Point Of Care Testing Facilities
10. Human NGAL Test Kit Market, by Distribution Channel
10.1. Introduction
10.2. Direct Tender
10.3. Distribution Partners
10.3.1. Global Distributors
10.3.2. Regional Distributors
10.4. Online Sales
11. Human NGAL Test Kit Market, by Application
11.1. Introduction
11.2. Diagnostic
11.2.1. Acute Kidney Injury Detection
11.2.2. Chronic Kidney Disease Monitoring
11.3. Research
11.4. Screening
11.4.1. Neonatal Screening
11.4.2. Population Screening
12. Human NGAL Test Kit Market, by Sample Type
12.1. Introduction
12.2. Plasma
12.2.1. Citrated Plasma
12.2.2. Edta Plasma
12.3. Serum
12.4. Urine
12.5. Whole Blood
13. Americas Human NGAL Test Kit Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Human NGAL Test Kit Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Human NGAL Test Kit Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Abbott Laboratories
16.3.2. BioPorto Diagnostics A/S
16.3.3. bioMérieux SA
16.3.4. Randox Laboratories Ltd.
16.3.5. BÜHLMANN Laboratories AG
16.3.6. Gentian AS
16.3.7. Diazyme Laboratories, Inc.
16.3.8. Sekisui Medical Co., Ltd.
16.3.9. BioVendor - Laboratorní medicína, a.s.
16.3.10. R&D Systems, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. HUMAN NGAL TEST KIT MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 8. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS HUMAN NGAL TEST KIT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS HUMAN NGAL TEST KIT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES HUMAN NGAL TEST KIT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES HUMAN NGAL TEST KIT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HUMAN NGAL TEST KIT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HUMAN NGAL TEST KIT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC HUMAN NGAL TEST KIT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC HUMAN NGAL TEST KIT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. HUMAN NGAL TEST KIT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. HUMAN NGAL TEST KIT MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. HUMAN NGAL TEST KIT MARKET: RESEARCHAI
FIGURE 26. HUMAN NGAL TEST KIT MARKET: RESEARCHSTATISTICS
FIGURE 27. HUMAN NGAL TEST KIT MARKET: RESEARCHCONTACTS
FIGURE 28. HUMAN NGAL TEST KIT MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. HUMAN NGAL TEST KIT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY DIRECT CLIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY DIRECT CLIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY INDIRECT CLIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY INDIRECT CLIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY AUTOMATED ELISA, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY AUTOMATED ELISA, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY MANUAL ELISA, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY MANUAL ELISA, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY IMMUNOTURBIDIMETRIC ASSAY, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY IMMUNOTURBIDIMETRIC ASSAY, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY ACADEMIC AND RESEARCH LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY ACADEMIC AND RESEARCH LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY HOSPITAL BASED LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY HOSPITAL BASED LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY POINT OF CARE TESTING FACILITIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY POINT OF CARE TESTING FACILITIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY DIRECT TENDER, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY DIRECT TENDER, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY DISTRIBUTION PARTNERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY DISTRIBUTION PARTNERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY GLOBAL DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY GLOBAL DISTRIBUTORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY REGIONAL DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY REGIONAL DISTRIBUTORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY DISTRIBUTION PARTNERS, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY DISTRIBUTION PARTNERS, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY ONLINE SALES, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY ONLINE SALES, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY ACUTE KIDNEY INJURY DETECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY ACUTE KIDNEY INJURY DETECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY CHRONIC KIDNEY DISEASE MONITORING, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY CHRONIC KIDNEY DISEASE MONITORING, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY RESEARCH, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY RESEARCH, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY SCREENING, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY SCREENING, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY NEONATAL SCREENING, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY NEONATAL SCREENING, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY POPULATION SCREENING, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY POPULATION SCREENING, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY SCREENING, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY SCREENING, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY PLASMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY PLASMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY CITRATED PLASMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY CITRATED PLASMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY EDTA PLASMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY EDTA PLASMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY PLASMA, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY PLASMA, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY SERUM, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY SERUM, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY URINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY URINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL HUMAN NGAL TEST KIT MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS HUMAN NGAL TEST KIT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS HUMAN NGAL TEST KIT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS HUMAN NGAL TEST KIT MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS HUMAN NGAL TEST KIT MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS HUMAN NGAL TEST KIT MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS HUMAN NGAL TEST KIT MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS HUMAN NGAL TEST KIT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS HUMAN NGAL TEST KIT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS HUMAN NGAL TEST KIT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS HUMAN NGAL TEST KIT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS HUMAN NGAL TEST KIT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS HUMAN NGAL TEST KIT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS HUMAN NGAL TEST KIT MARKET SIZE, BY DISTRIBUTION PARTNERS, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS HUMAN NGAL TEST KIT MARKET SIZE, BY DISTRIBUTION PARTNERS, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS HUMAN NGAL TEST KIT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS HUMAN NGAL TEST KIT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS HUMAN NGAL TEST KIT MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS HUMAN NGAL TEST KIT MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS HUMAN NGAL TEST KIT MARKET SIZE, BY SCREENING, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS HUMAN NGAL TEST KIT MARKET SIZE, BY SCREENING, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS HUMAN NGAL TEST KIT MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS HUMAN NGAL TEST KIT MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS HUMAN NGAL TEST KIT MARKET SIZE, BY PLASMA, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS HUMAN NGAL TEST KIT MARKET SIZE, BY PLASMA, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS HUMAN NGAL TEST KIT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS HUMAN NGAL TEST KIT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES HUMAN NGAL TEST KIT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES HUMAN NGAL TEST KIT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES HUMAN NGAL TEST KIT MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES HUMAN NGAL TEST KIT MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES HUMAN NGAL TEST KIT MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES HUMAN NGAL TEST KIT MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES HUMAN NGAL TEST KIT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES HUMAN NGAL TEST KIT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES HUMAN NGAL TEST KIT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES HUMAN NGAL TEST KIT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES HUMAN NGAL TEST KIT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES HUMAN NGAL TEST KIT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES HUMAN NGAL TEST KIT MARKET SIZE, BY DISTRIBUTION PARTNERS, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES HUMAN NGAL TEST KIT MARKET SIZE, BY DISTRIBUTION PARTNERS, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES HUMAN NGAL TEST KIT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES HUMAN NGAL TEST KIT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES HUMAN NGAL TEST KIT MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES HUMAN NGAL TEST KIT MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES HUMAN NGAL TEST KIT MARKET SIZE, BY SCREENING, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES HUMAN NGAL TEST KIT MARKET SIZE, BY SCREENING, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES HUMAN NGAL TEST KIT MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES HUMAN NGAL TEST KIT MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES HUMAN NGAL TEST KIT MARKET SIZE, BY PLASMA, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES HUMAN NGAL TEST KIT MARKET SIZE, BY PLASMA, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES HUMAN NGAL TEST KIT MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES HUMAN NGAL TEST KIT MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 149. CANADA HUMAN NGAL TEST KIT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 150. CANADA HUMAN NGAL TEST KIT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 151. CANADA HUMAN NGAL TEST KIT MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 152. CANADA HUMAN NGAL TEST KIT MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 153. CANADA HUMAN NGAL TEST KIT MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2024 (USD MILLION)
TABLE 154. CANADA HUMAN NGAL TEST KIT MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2025-2030 (USD MILLION)
TABLE 155. CANADA HUMAN NGAL TEST KIT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 156. CANADA HUMAN NGAL TEST KIT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 157. CANADA HUMAN NGAL TEST KIT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 158. CANADA HUMAN NGAL TEST KIT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 159. CANADA HUMAN NGAL TEST KIT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 160. CANADA HUMAN NGAL TEST KIT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 161. CANADA HUMAN NGAL TEST KIT MARKET SIZE, BY DISTRIBUTION PARTNERS, 2018-2024 (USD MILLION)
TABLE 162. CANADA HUMAN NGAL TEST KIT MARKET SIZE, BY DISTRIBUTION PARTNERS, 2025-2030 (USD MILLION)
TABLE 163. CANADA HUMAN NGAL TEST KIT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 164. CANADA HUMAN NGAL TEST KIT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 165. CANADA HUMAN NGAL TEST KIT MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 166. CANADA HUMAN NGAL TEST KIT MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 167. CANADA HUMAN NGAL TEST KIT MARKET SIZE, BY SCREENING, 2018-2024 (USD MILLION)
TABLE 168. CANADA HUMAN NGAL TEST KIT MARKET SIZE, BY SCREENING, 2025-2030 (USD MILLION)
TABLE 169. CANADA HUMAN NGAL TEST KIT MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 170. CANADA HUMAN NGAL TEST KIT MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 171. CANADA HUMAN NGAL TEST KIT MARKET SIZE, BY PLASMA, 2018-2024 (USD MILLION)
TABLE 172. CANADA HUMAN NGAL TEST KIT MARKET SIZE, BY PLASMA, 2025-2030 (USD MILLION)
TABLE 173. MEXICO HUMAN NGAL TEST KIT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 174. MEXICO HUMAN NGAL TEST KIT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 175. MEXICO HUMAN NGAL TEST KIT MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 176. MEXICO HUMAN NGAL TEST KIT MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 177. MEXICO HUMAN NGAL TEST KIT MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2024 (USD MILLION)
TABLE 178. MEXICO HUMAN NGAL TEST KIT MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2025-2030 (USD MILLION)
TABLE 179. MEXICO HUMAN NGAL TEST KIT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 180. MEXICO HUMAN NGAL TEST KIT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 181. MEXICO HUMAN NGAL TEST KIT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 182. MEXICO HUMAN NGAL TEST KIT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 183. MEXICO HUMAN NGAL TEST KIT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 184. MEXICO HUMAN NGAL TEST KIT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 185. MEXICO HUMAN NGAL TEST KIT MARKET SIZE, BY DISTRIBUTION PARTNERS, 2018-2024 (USD MILLION)
TABLE 186. MEXICO HUMAN NGAL TEST KIT MARKET SIZE, BY DISTRIBUTION PARTNERS, 2025-2030 (USD MILLION)
TABLE 187. MEXICO HUMAN NGAL TEST KIT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 188. MEXICO HUMAN NGAL TEST KIT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 189. MEXICO HUMAN NGAL TEST KIT MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 190. MEXICO HUMAN NGAL TEST KIT MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 191. MEXICO HUMAN NGAL TEST KIT MARKET SIZE, BY SCREENING, 2018-2024 (USD MILLION)
TABLE 192. MEXICO HUMAN NGAL TEST KIT MARKET SIZE, BY SCREENING, 2025-2030 (USD MILLION)
TABLE 193. MEXICO HUMAN NGAL TEST KIT MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 194. MEXICO HUMAN NGAL TEST KIT MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 195. MEXICO HUMAN NGAL TEST KIT MARKET SIZE, BY PLASMA, 2018-2024 (USD MILLION)
TABLE 196. MEXICO HUMAN NGAL TEST KIT MARKET SIZE, BY PLASMA, 2025-2030 (USD MILLION)
TABLE 197. BRAZIL HUMAN NGAL TEST KIT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 198. BRAZIL HUMAN NGAL TEST KIT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 199. BRAZIL HUMAN NGAL TEST KIT MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 200. BRAZIL HUMAN NGAL TEST KIT MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 201. BRAZIL HUMAN NGAL TEST KIT MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2024 (USD MILLION)
TABLE 202. BRAZIL HUMAN NGAL TEST KIT MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2025-2030 (USD MILLION)
TABLE 203. BRAZIL HUMAN NGAL TEST KIT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 204. BRAZIL HUMAN NGAL TEST KIT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 205. BRAZIL HUMAN NGAL TEST KIT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 206. BRAZIL HUMAN NGAL TEST KIT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 207. BRAZIL HUMAN NGAL TEST KIT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 208. BRAZIL HUMAN NGAL TEST KIT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 209. BRAZIL HUMAN NGAL TEST KIT MARKET SIZE, BY DISTRIBUTION PARTNERS, 2018-2024 (USD MILLION)
TABLE 210. BRAZIL HUMAN NGAL TEST KIT MARKET SIZE, BY DISTRIBUTION PARTNERS, 2025-2030 (USD MILLION)
TABLE 211. BRAZIL HUMAN NGAL TEST KIT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 212. BRAZIL HUMAN NGAL TEST KIT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 213. BRAZIL HUMAN NGAL TEST KIT MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 214. BRAZIL HUMAN NGAL TEST KIT MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 215. BRAZIL HUMAN NGAL TEST KIT MARKET SIZE, BY SCREENING, 2018-2024 (USD MILLION)
TABLE 216. BRAZIL HUMAN NGAL TEST KIT MARKET SIZE, BY SCREENING, 2025-2030 (USD MILLION)
TABLE 217. BRAZIL HUMAN NGAL TEST KIT MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 218. BRAZIL HUMAN NGAL TEST KIT MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 219. BRAZIL HUMAN NGAL TEST KIT MARKET SIZE, BY PLASMA, 2018-2024 (USD MILLION)
TABLE 220. BRAZIL HUMAN NGAL TEST KIT MARKET SIZE, BY PLASMA, 2025-2030 (USD MILLION)
TABLE 221. ARGENTINA HUMAN NGAL TEST KIT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 222. ARGENTINA HUMAN NGAL TEST KIT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 223. ARGENTINA HUMAN NGAL TEST KIT MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 224. ARGENTINA HUMAN NGAL TEST KIT MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 225. ARGENTINA HUMAN NGAL TEST KIT MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2024 (USD MILLION)
TABLE 226. ARGENTINA HUMAN NGAL TEST KIT MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2025-2030 (USD MILLION)
TABLE 227. ARGENTINA HUMAN NGAL TEST KIT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 228. ARGENTINA HUMAN NGAL TEST KIT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 229. ARGENTINA HUMAN NGAL TEST KIT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 230. ARGENTINA HUMAN NGAL TEST KIT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 231. ARGENTINA HUMAN NGAL TEST KIT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 232. ARGENTINA HUMAN NGAL TEST KIT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 233. ARGENTINA HUMAN NGAL TEST KIT MARKET SIZE, BY DISTRIBUTION PARTNERS, 2018-2024 (USD MILLION)
TABLE 234. ARGENTINA HUMAN NGAL TEST KIT MARKET SIZE, BY DISTRIBUTION PARTNERS, 2025-2030 (USD MILLION)
TABLE 235. ARGENTINA HUMAN NGAL TEST KIT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 236. ARGENTINA HUMAN NGAL TEST KIT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 237. ARGENTINA HUMAN NGAL TEST KIT MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 238. ARGENTINA HUMAN NGAL TEST KIT MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 239. ARGENTINA HUMAN NGAL TEST KIT MARKET SIZE, BY SCREENING, 2018-2024 (USD MILLION)
TABLE 240. ARGENTINA HUMAN NGAL TEST KIT MARKET SIZE, BY SCREENING, 2025-2030 (USD MILLION)
TABLE 241. ARGENTINA HUMAN NGAL TEST KIT MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 242. ARGENTINA HUMAN NGAL TEST KIT MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 243. ARGENTINA HUMAN NGAL TEST KIT MARKET SIZE, BY PLASMA, 2018-2024 (USD MILLION)
TABLE 244. ARGENTINA HUMAN NGAL TEST KIT MARKET SIZE, BY PLASMA, 2025-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA HUMAN NGAL TEST KIT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA HUMAN NGAL TEST KIT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA HUMAN NGAL TEST KIT MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA HUMAN NGAL TEST KIT MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA HUMAN NGAL TEST KIT MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2024 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA HUMAN NGAL TEST KIT MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2025-2030 (USD MILLION)
TABLE 251. EUROPE, MIDDLE EAST & AFRICA HUMAN NGAL TEST KIT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 252. EUROPE, MIDDLE EAST & AFRICA HUMAN NGAL TEST KIT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 253. EUROPE, MIDDLE EAST & AFRICA HUMAN NGAL TEST KIT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 254. EUROPE, MIDDLE EAST & AFRICA HUMAN NGAL TEST KIT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 255. EUROPE, MIDDLE EAST & AFRICA HUMAN NGAL TEST KIT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 256. EUROPE, MIDDLE EAST & AFRICA HUMAN NGAL TEST KIT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 257. EUROPE, MIDDLE EAST & AFRICA HUMAN NGAL TEST KIT MARKET SIZE, BY DISTRIBUTION PARTNERS, 2018-2024 (USD MILLION)
TABLE 258. EUROPE, MIDDLE EAST & AFRICA HUMAN NGAL TEST KIT MARKET SIZE, BY DISTRIBUTION PARTNERS, 2025-2030 (USD MILLION)
TABLE 259. EUROPE, MIDDLE EAST & AFRICA HUMAN NGAL TEST KIT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 260. EUROPE, MIDDLE EAST & AFRICA HUMAN NGAL TEST KIT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 261. EUROPE, MIDDLE EAST & AFRICA HUMAN NGAL TEST KIT MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 262. EUROPE, MIDDLE EAST & AFRICA HUMAN NGAL TEST KIT MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 263. EUROPE, MIDDLE EAST & AFRICA HUMAN NGAL TEST KIT MARKET SIZE, BY SCREENING, 2018-2024 (USD MILLION)
TABLE 264. EUROPE, MIDDLE EAST & AFRICA HUMAN NGAL TEST KIT MARKET SIZE, BY SCREENING, 2025-2030 (USD MILLION)
TABLE 265. EUROPE, MIDDLE EAST & AFRICA HUMAN NGAL TEST KIT MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 266. EUROPE, MIDDLE EAST & AFRICA HUMAN NGAL TEST KIT MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 267. EUROPE, MIDDLE EAST & AFRICA HUMAN NGAL TEST KIT MARKET SIZE, BY PLASMA, 2018-2024 (USD MILLION)
TABLE 268. EUROPE, MIDDLE EAST & AFRICA HUMAN NGAL TEST KIT MARKET SIZE, BY PLASMA, 2025-2030 (USD MILLION)
TABLE 269. EUROPE, MIDDLE EAST & AFRICA HUMAN NGAL TEST KIT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 270. EUROPE, MIDDLE EAST & AFRICA HUMAN NGAL TEST KIT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 271. UNITED KINGDOM HUMAN NGAL TEST KIT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 272. UNITED KINGDOM HUMAN NGAL TEST KIT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 273. UNITED KINGDOM HUMAN NGAL TEST KIT MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 274. UNITED KINGDOM HUMAN NGAL TEST KIT MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 275. UNITED KINGDOM HUMAN NGAL TEST KIT MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2024 (USD MILLION)
TABLE 276. UNITED KINGDOM HUMAN NGAL TEST KIT MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2025-2030 (USD MILLION)
TABLE 277. UNITED KINGDOM HUMAN NGAL TEST KIT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 278. UNITED KINGDOM HUMAN NGAL TEST KIT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 279. UNITED KINGDOM HUMAN NGAL TEST KIT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 280. UNITED KINGDOM HUMAN NGAL TEST KIT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM HUMAN NGAL TEST KIT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 282. UNITED KINGDOM HUMAN NGAL TEST KIT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 283. UNITED KINGDOM HUMAN NGAL TEST KIT MARKET SIZE, BY DISTRIBUTION PARTNERS, 2018-2024 (USD MILLION)
TABLE 284. UNITED KINGDOM HUMAN NGAL TEST KIT MARKET SIZE, BY DISTRIBUTION PARTNERS, 2025-2030 (USD MILLION)
TABLE 285. UNITED KINGDOM HUMAN NGAL TEST KIT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 286. UNITED KINGDOM HUMAN NGAL TEST KIT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 287. UNITED KINGDOM HUMAN NGAL TEST KIT MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 288. UNITED KINGDOM HUMAN NGAL TEST KIT MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 289. UNITED KINGDOM HUMAN NGAL TEST KIT MARKET SIZE, BY SCREENING, 2018-2024 (USD MILLION)
TABLE 290. UNITED KINGDOM HUMAN NGAL TEST KIT MARKET SIZE, BY SCREENING, 2025-2030 (USD MILLION)
TABLE 291. UNITED KINGDOM HUMAN NGAL TEST KIT MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 292. UNITED KINGDOM HUMAN NGAL TEST KIT MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 293. UNITED KINGDOM HUMAN NGAL TEST KIT MARKET SIZE, BY PLASMA, 2018-2024 (USD MILLION)
TABLE 294. UNITED KINGDOM HUMAN NGAL TEST KIT MARKET SIZE, BY PLASMA, 2025-2030 (USD MILLION)
TABLE 295. GERMANY HUMAN NGAL TEST KIT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 296. GERMANY HUMAN NGAL TEST KIT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 297. GERMANY HUMAN NGAL TEST KIT MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 298. GERMANY HUMAN NGAL TEST KIT MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 299. GERMANY HUMAN NGAL TEST KIT MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2024 (USD MILLION)
TABLE 300. GERMANY HUMAN NGAL TEST KIT MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2025-2030 (USD MILLION)
TABLE 301. GERMANY HUMAN NGAL TEST KIT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 302. GERMANY HUMAN NGAL TEST KIT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 303. GERMANY HUMAN NGAL TEST KIT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 304. GERMANY HUMAN NGAL TEST KIT MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 305. GERMANY HUMAN NGAL TEST KIT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 306. GERMANY HUMAN NGAL TEST KIT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 307. GERMANY HUMAN NGAL TEST KIT MARKET SIZE, BY DISTRIBUTION PARTNERS, 2018-2024 (USD MILLION)
TABLE 308. GERMANY HUMAN NGAL TEST KIT MARKET SIZE, BY DISTRIBUTION PARTNERS, 2025-2030 (USD MILLION)
TABLE 309. GERMANY HUMAN NGAL TEST KIT MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 310. GERMANY HUMAN NGAL TEST KIT MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 311. GERMANY HUMAN NGAL TEST KIT MARKET SIZE, BY DIAGNOSTIC, 2018-2024 (USD MILLION)
TABLE 312. GERMANY HUMAN NGAL TEST KIT MARKET SIZE, BY DIAGNOSTIC, 2025-2030 (USD MILLION)
TABLE 313. GERMANY HUMAN NGAL TEST KIT MARKET SIZE, BY SCREENING, 2018-2024 (USD MILLION)
TABLE 314. GERMANY HUMAN NGAL TEST KIT MARKET SIZE, BY SCREENING, 2025-2030 (USD MILLION)
TABLE 315. GERMANY HUMAN NGAL TEST KIT MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
TABLE 316. GERMANY HUMAN NGAL TEST KIT MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
TABLE 317. GERMANY HUMAN NGAL TEST KIT MARKET SIZE, BY PLASMA, 2018-2024 (USD MILLION)
TABLE 318. GERMANY HUMAN NGAL TEST KIT MARKET SIZE, BY PLASMA, 2025-2030 (USD MILLION)
TABLE 319. FRANCE HUMAN NGAL TEST KIT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 320. FRANCE HUMAN NGAL TEST KIT MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 321. FRANCE HUMAN NGAL TEST KIT MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 322. FRANCE HUMAN NGAL TEST KIT MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 323. FRANCE HUMAN NGAL TEST KIT MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2018-2024 (USD MILLION)
TABLE 324. FRANCE HUMAN NGAL TEST KIT MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, 2025-2030 (USD MILLION)
TABLE 325. FRANCE HUMAN NGAL TEST KIT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 326. FRANCE HUMAN NGAL TEST KIT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 327. FRANCE HUMAN NGAL TEST KIT MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 328.

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Human NGAL Test Kit market report include:
  • Abbott Laboratories
  • BioPorto Diagnostics A/S
  • bioMérieux SA
  • Randox Laboratories Ltd.
  • BÜHLMANN Laboratories AG
  • Gentian AS
  • Diazyme Laboratories, Inc.
  • Sekisui Medical Co., Ltd.
  • BioVendor - Laboratorní medicína, a.s.
  • R&D Systems, Inc.

Related Reports

Human Lipocalin-2/NGAL ELISA Kit Market - Global Forecast 2025-2030 - Product Image

Human Lipocalin-2/NGAL ELISA Kit Market - Global Forecast 2025-2030

  • Report
  • 195 Pages
  • Global
From
NGAL ELISA Kit Market - Global Forecast 2025-2030 - Product Image

NGAL ELISA Kit Market - Global Forecast 2025-2030

  • Report
  • 184 Pages
  • Global
From
Renal Biomarkers - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030) - Product Image

Renal Biomarkers - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

  • Report
  • 154 Pages
  • Global
From
Renal Biomarkers - Global Strategic Business Report - Product Image

Renal Biomarkers - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Roche Diagnostics International Ltd - Product Pipeline Analysis, 2025 Update - Product Image

Roche Diagnostics International Ltd - Product Pipeline Analysis, 2025 Update

  • Company Profile
  • 333 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.